The cardioprotective effect of sevoflurane depends on protein kinase C activation, opening of mitochondrial K(+)(ATP) channels, and the production of reactive oxygen species

Anesth Analg. 2003 Nov;97(5):1370-1376. doi: 10.1213/01.ANE.0000081786.74722.DA.

Abstract

Several studies suggest that the cardioprotective effect of sevoflurane depends on protein kinase C (PKC) activation, mitochondrial K(+)(ATP) channel (mitoK(+)(ATP)) opening, and reactive oxygen species (ROS). However, evidence for their involvement was obtained in separate experimental models. Here, we studied the relative roles of PKC, mitoK(+)(ATP), and ROS in sevoflurane-induced cardioprotection in one model. Rat trabeculae were subjected to simulated ischemia by applying metabolic inhibition (MI) through buffer containing NaCN, followed by 60-min reperfusion. Recovery of active force (F(a)) was assessed as percentage of pre-MI force. In time controls, F(a) amounted 60% +/- 5% at the end of the experiment. The recovery of F(a) after MI was reduced to 28% +/- 5% (P = 0.045 versus time control), whereas sevoflurane reversed the detrimental effect of MI (F(a) recovery, 67% +/- 8%; P = 0.01 versus MI). The PKC inhibitor chelerythrine, the mitoK(+)(ATP) inhibitor 5-hydroxy decanoic, and the ROS scavenger N-(2-mercaptopropionyl)-glycine all completely abolished the protective effect of sevoflurane (recovery of F(a), 31% +/- 8%, 33% +/- 8%, and 24% +/- 9% for chelerythrine, 5-hydroxy decanoic, and N-(2-mercaptopropionyl)-glycine, respectively). In conclusion, PKC activation, mitoK(+)(ATP) channel opening, and ROS production are all essential for sevoflurane-induced cardioprotection. These signaling events are arranged in series within a common signaling pathway, rather than in parallel cascades. Our findings implicate that the perioperative use of sevoflurane preserves cardiac function by preventing ischemia-reperfusion injury.

Implications: Protein kinase C, mitochondrial K(+)(ATP) channels and reactive oxygen species act within one downstream signaling pathway in mediating the cardioprotective effect of sevoflurane.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP-Binding Cassette Transporters
  • Anesthetics, Inhalation / pharmacology*
  • Animals
  • Enzyme Activation / drug effects
  • Enzyme Inhibitors / pharmacology
  • Free Radical Scavengers / pharmacology
  • Heart Diseases / enzymology
  • Heart Diseases / prevention & control*
  • KATP Channels
  • Male
  • Methyl Ethers / pharmacology*
  • Mitochondria, Heart / drug effects
  • Mitochondria, Heart / enzymology
  • Mitochondria, Heart / metabolism*
  • Myocardial Infarction / etiology
  • Myocardial Infarction / pathology
  • Myocardial Infarction / prevention & control
  • Myocardial Ischemia / complications
  • Myocardial Ischemia / pathology
  • Potassium Channel Blockers / pharmacology
  • Potassium Channels / drug effects
  • Potassium Channels / metabolism*
  • Potassium Channels, Inwardly Rectifying
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / metabolism*
  • Rats
  • Rats, Wistar
  • Reactive Oxygen Species / metabolism*
  • Sevoflurane
  • Signal Transduction / drug effects

Substances

  • ATP-Binding Cassette Transporters
  • Anesthetics, Inhalation
  • Enzyme Inhibitors
  • Free Radical Scavengers
  • KATP Channels
  • Methyl Ethers
  • Potassium Channel Blockers
  • Potassium Channels
  • Potassium Channels, Inwardly Rectifying
  • Reactive Oxygen Species
  • uK-ATP-1 potassium channel
  • Sevoflurane
  • Protein Kinase C